Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYDAS-T Domain 2: SRA515 + ASTX727 in higher-risk MDS/low-blast AML
ACTRN12622001302741Phase 2Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of amcenestrant and inqovi in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Safety and tolerability of SRA515 in combination with ASTX727, Recommended Phase 2 Dose and 1 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
amcenestrantinqovi
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12622001302741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001302741.